This Kefir Yeast Kills 78% of Staph Biofilms Tied to Eczema Flares

For anyone whose eczema flares keep returning no matter how carefully they moisturize, there's a good chance a stubborn bacterium is riding along on their skin. Staphylococcus aureus, the same bacterium behind many skin and wound infections, colonizes eczema-prone skin far more aggressively than healthy skin, and the more it takes hold, the worse flares tend to get. A new laboratory study built around an unlikely source, yeast pulled from homemade kefir, found that byproducts from that yeast can tear apart the protective shields Staph bacteria use to survive on skin. It's early, dish-based science, but it's the kind of finding that makes microbiome researchers sit up.

Key Takeaways

• A postbiotic (non-living compound) from Pichia kudriavzevii, a yeast found in homemade kefir, eradicated about 78% of Staphylococcus aureus biofilms taken from eczema patients in lab tests.
• The same extracellular vesicles reduced inflammatory signaling (IL-6, IL-8) and drove over 90% wound closure in skin-cell assays within 24 hours.
• This is entirely in vitro work; nobody has tested it on animal or human skin, so it is not a proven eczema treatment.
• Worth mentioning to a dermatologist as an emerging research direction, not something to look for in a skincare product yet.

Kefir Yeast Postbiotics Dismantle Staph Skin Biofilms

Researchers found that postbiotics (beneficial compounds a microbe produces, not the living microbe itself, per the ISAPP consensus definition) derived from Pichia kudriavzevii, a yeast isolated from homemade kefir, can break down the biofilms Staphylococcus aureus forms on skin, according to a study published in Frontiers in Microbiology. The team tested two postbiotic preparations from the yeast: a cell-free supernatant (CFS, the filtered liquid still carrying the molecules the yeast secreted) and extracellular vesicles (EVs, tiny lipid-wrapped packages cells release that ferry bioactive cargo). Both were pitted against S. aureus and Candida parapsilosis, a fungus, isolated directly from the skin of people with atopic dermatitis (AD), the clinical name for eczema.

Why Eczema Patients Should Care About Staph Biofilms

People with eczema deal with a vicious cycle: skin barrier damage lets Staphylococcus aureus move in, and once it forms a biofilm (a slimy, self-built shield that lets bacteria cluster together and resist both the immune system and antibiotics), it becomes far harder to clear and tends to trigger more inflammation and itching, which damages the barrier further. This study zeroed in on that exact bottleneck. The postbiotics weren't uniformly effective: S. aureus showed high vulnerability to both preparations, while Candida parapsilosis proved more tolerant, an asymmetry that matters given how Staph strain behavior varies patient to patient in eczema, suggesting a future postbiotic treatment might need pairing with something else to handle fungal co-infections rather than acting as a single silver bullet.

How Researchers Tested Postbiotics Against Real Patient Isolates

The credibility of this study rests on where its test subjects came from: the S. aureus and C. parapsilosis strains weren't lab reference strains but isolates collected from atopic dermatitis patients, meaning the microbes behaved like the real, clinically relevant version of the problem rather than a tidy lab surrogate. At a concentration of 200 micrograms per milliliter, the extracellular vesicles eradicated roughly 78% of S. aureus biofilms and about 60% of C. parapsilosis biofilms in dish-based assays. The researchers also ran the postbiotics through human keratinocyte (skin cell) infection assays, and both preparations reduced how much the microbes could adhere to and invade those cells.

What a Kefir Postbiotic Could Mean for Your Skin, Someday

It's worth being direct about what this study doesn't show: nobody has applied this postbiotic to actual eczema-affected skin, in a person or an animal, and no cream or supplement containing it exists or is proven to work. What the lab data does suggest is a mechanism worth watching. Beyond killing biofilms, the extracellular vesicles achieved more than 90% wound closure within 24 hours in a keratinocyte scratch assay (a standard lab test measuring how fast a gap scraped into a sheet of skin cells closes, used as a proxy for wound healing), and both postbiotic preparations lowered levels of the inflammatory signaling proteins IL-6 and IL-8, molecules strongly tied to the redness, swelling, and itch of an eczema flare. If a reader deals with recurrent, hard-to-clear eczema flares that track with skin infections, this is a reasonable study to mention to a dermatologist as background, not a reason to seek out kefir-derived skincare products, since none on the market today have been tested this way.

The Study's Biggest Limitation: It Never Left the Lab Dish

This is entirely in vitro (test-tube and cell-culture) work. Every result here, the biofilm eradication percentages, the wound-closure rate, the cytokine drops, comes from isolated bacteria, fungi, and skin cells in dishes, not from living skin, let alone a person with eczema. Whether a postbiotic that performs this well on a plastic dish would survive, penetrate skin, and act the same way on inflamed, barrier-compromised human skin is genuinely unknown. The study's authors disclosed no commercial or financial conflicts of interest and reported receiving no external funding, which strengthens confidence the numbers weren't tilted to sell a product; this is proof of concept, not proof of benefit.

What Comes Next for Postbiotic Eczema Research

The logical next step is testing on an actual eczema skin model, whether in animals or in more complex, multi-layered skin-equivalent tissue, before anyone talks about a topical product. Researchers in postbiotic and probiotic skin therapy generally treat this in vitro stage as the first of at least two or three more validation steps before human trials become plausible, so it's realistic to expect at least a few years before a follow-up study answers whether the effect holds on real skin.

Common Questions

Is this the same as taking a probiotic or eating kefir for eczema? No. The study tested purified postbiotic compounds extracted from a specific yeast strain, not live kefir or a probiotic supplement, and it didn't test whether eating kefir affects eczema.

Does this mean Staph aureus causes eczema? Not according to this study. Staph aureus colonization is well established as a factor that worsens eczema flares and inflammation, but the relationship is a two-way street, and this study didn't test causation, only the postbiotic's ability to kill biofilms in a dish.

Could this postbiotic become a skincare ingredient? Possibly, eventually, but not yet. It hasn't been tested on human or animal skin, so any commercial product claiming this benefit today would be getting ahead of the evidence.

What's the difference between the two postbiotic types tested? Cell-free supernatant (CFS) is the filtered liquid containing everything the yeast secreted, while extracellular vesicles (EVs) are smaller, purified lipid particles pulled from that liquid; in this study, EVs were generally the stronger performer against biofilms and wound healing.

References

1. Angela Maione, Annalisa Buonanno, Lea Di Massa, et al. (2026). Targeting polymicrobial skin infections in atopic dermatitis: role of Pichia kudriavzevii postbiotics as innovative tools for human health. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2026.1919460
2. ISAPP consensus postbiotic definition, Nature Reviews Gastroenterology & Hepatology. Nature. https://www.nature.com/articles/s41575-021-00440-6
3. Zhongjie Wang, Claudia Hülpüsch, Claudia Traidl-Hoffmann, Matthias Reiger, Michael Schloter (2024). Understanding the role of Staphylococcus aureus in atopic dermatitis: strain diversity, microevolution, and prophage influences. Frontiers in Medicine. https://doi.org/10.3389/fmed.2024.1480257